На главную
Результаты поиска “Drug development plan template”
Drug Development Project Template
Smooth out your drug development process with a timeline that coordinates CMC, Nonclinical, and Clinical functions in an integrated timeline. All tasks are coupled with specific FDA/EMEA regulatory requirements. You can be assured nothing is left out, and everyone on the team understands the entire scope of the project. Never be surprised again.
Просмотров: 559 Tim Wurst
How To Write a Business Plan To Start Your Own Business
Start Your Own Business by Writing Business Plan. How to write a successful business plan for successful startups. Step By Step - How to write a business plan an effectively for starting your own business. Watch 11 Elements of Sample Business Plan - https://www.youtube.com/watch?v=i1b0_UdeOTI TOP 10 TIPS Before Starting Your OWN BUSINESS : https://youtu.be/wxyGeUkPYFM Join our Young Entrepreneurs Forum - http://www.youngentrepreneursforum.com/ #youngentrepreneursforum Do you need a business plan for successful startups in India, USA, UK & Canada. Starting an own business needs working plan which compiles some important details about product & company. Problem Solving Skills To Start a Small Business - https://www.youtube.com/watch?v=I9Ho3jFvq6I #startsmallbusiness 9 Steps For Writing a Business Plan - Required Steps to Write a Business Plan for your company or service. Step 1 - Define your vision 1:16 Step 2 - Set your goals and objectives for the business 1:50 Step 3 - Define your Unique Selling Proposition 2:29 Step 4 - Know your market 3:02 Step 5 - Know your customer 3:57 Step 6 - Research the demand for your business 4:47 Step 7 - Set your marketing goals 5:52 Step 8 - Define your marketing strategy 6:38 Step 9 - Take Action! 7:20 These all Steps are very important while you are writing a business plan for starting your own business. Life of Riley by Kevin MacLeod is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1400054 Artist: http://incompetech.com/ You must have to focus on Idea, Product,Strategy,Team, Marketing and Profit while you are writing business plan for your successful stratups.
Просмотров: 1342208 Young Entrepreneurs Forum
IPPCR 2016: Concepts in Pharmaceutical Development Project Management
IPPCR 2016: Concepts in Pharmaceutical Development Project Management Air date: Monday, February 01, 2016, 5:00:00 PM Category: IPPCR Runtime: 00:48:04 Description: The Introduction to the Principles and Practice of Clinical Research (IPPCR) is a course to train participants on how to effectively conduct clinical research. The course focuses on the spectrum of clinical research and the research process by highlighting epidemiologic methods, study design, protocol preparation, patient monitoring, quality assurance, and Food and Drug Administration (FDA) issues. For more information go to http://clinicalcenter.nih.gov/training/training/ippcr1.html Author: Christopher D. Breder, M.D., Ph.D., FDA Permanent link: http://videocast.nih.gov/launch.asp?19461
Просмотров: 6130 nihvcast
Clinical Trials Medical Device & Drug Development Education Planning Session
Want to stay competitive in your career? Join us for a free Webinar, and learn about the skills needed to be successful in the current job market. You'll get information on the latest developments, industry trends, and more! We will also provide you with current options for financial assistance, career planning resources, and supply you with the courses within our Clinical Trials Certificate program that are being offered in the upcoming quarters.
Просмотров: 807 UCI Division of Continuing Education
creative ideas for pharmaceutical marketing
It will be a huge turn over in the pharmacist life or career of a pharmacist, if he try to fix his skills and passion to crate an android app which acts as a communicator between patient and physician for easy access of services.
Просмотров: 15920 Prestige Pharmacy Profession
Speeding Drug Development through Impurity Control Strategies
Dr. Steven Baertschi delivered this talk in South San Francisco, CA on October 31, 2018. Development and implementation of impurity control strategies is a complicated, yet critical process necessary to ensure overall pharmaceutical product quality and patient safety. Existing guidelines for control of new impurities in drug substances and new drug products (ICH Q3A/Q3B, USP Chapters 476 & 1086) apply to commercial products or products in late-stage clinical development (Phase 3). In addition, guidance for mutagenic impurities (ICH M7), which covers early clinical development through commercialization, is a relatively new guideline and questions regarding its implementation remain. The lack of regulatory guidance regarding impurity controls at early stages of clinical development (prior to Phase 3) provides both questions and opportunities for the development of effective control strategies. This talk focuses on risk-based, chemistry-driven approaches to speeding the development of organic impurity control strategies throughout clinical development. Relevant examples and references are provided.
Просмотров: 110 Regis Technologies, Inc.
How do we speed up Parkinson's drug development?
Parkinson's UK and the University of Sheffield have launched a £1 million virtual biotech company to create new treatments for Parkinson's. Dr Richard Mead explains more about this pioneering approach. Parkinson's future drug innovations https://youtu.be/NUeEFVy2Ojw Subscribe for weekly Parkinson's videos http://bit.ly/ParkinsonsUKYouTube
Просмотров: 659 Parkinson's UK
Pharmaceutical Product Lifecycle Management
The presentation gives details of Production Life Cycle begining from lab to final launch, applicable in pharmaceutical and Biopharmaceutical industry.
Просмотров: 3971 Biobridge Healthcare
Drug Development Process - Animated Infographic
An animated infographic that outlines the drug development process
Просмотров: 415 Kevin Schiel
Decision Tree Tutorial in 7 minutes with Decision Tree Analysis & Decision Tree Example (Basic)
Clicked here http://www.MBAbullshit.com/ and OMG wow! I'm SHOCKED how easy.. No wonder others goin crazy sharing this??? Share it with your other friends too! Fun MBAbullshit.com is filled with easy quick video tutorial reviews on topics for MBA, BBA, and business college students on lots of topics from Finance or Financial Management, Quantitative Analysis, Managerial Economics, Strategic Management, Accounting, and many others. Cut through the bullshit to understand MBA!(Coming soon!) http://www.youtube.com/watch?v=a5yWr1hr6QY
Просмотров: 541198 MBAbullshitDotCom
Using Model-Based Meta-Analysis to Improve Decision-Making in Drug Development
Making the right choices in drug development often means the difference between getting a new medication to patients and it ending up in the scrap heap of failed programs. There is a surfeit of publicly available information on approved drugs as well as those currently in development. How can sponsors turn clinical trial data into understanding that helps chart the course for investigational drugs? Model-based meta-analysis (MBMA) is an emerging methodology that quantifies clinical trial efficacy, tolerability, and safety information to enable strategic drug development decisions. The strategy involves a systematic search and tabulation of summary results from public sources which may be combined with proprietary clinical trial data. These data are then analyzed using nonlinear regression models which characterize the impacts of drug class, drug, dose, and time on the response(s) of interest. In this webinar, Dr. Leon Bax presented several case studies that illustrate how MBMA was used to help sponsors: - Position a drug within the competitive landscape - Optimize clinical trial design - Inform portfolio and marketing decisions to ensure commercial success
Просмотров: 562 Certara
Understanding New Drug Applications (NDAs)
Marketing application submissions, including NDAs, BLAs, and PMAs in the US, are the culmination of years of research and the final hurdle before a product makes it to market. This webinar will help you understand what is involved in an NDA including regulatory strategy, data integration and readiness, and electronic publishing, and provide tips that can help you avoid common pitfalls in the submissions process.
Просмотров: 410 RhoInc1984
Drug development services at LGC
The challenges in drug development put increasing emphasis on generating safety and efficacy information quickly and reliably. Planning and conducting preclinical and clinical studies is costly and time-consuming and the return on your investment is often measured in terms of pharmacokinetic (PK) and/or pharmacodynamic (PD) results generated by the bioanalytical laboratory. This means you need a laboratory partner who you can trust and who shares your passion and enthusiasm to progress your project. LGC has a world-class bioanalytical capability and a team of scientists dedicated to providing on time, high quality data to help you make critical decisions on the safety and efficacy of your molecule. Supported by the latest mass spectrometry and immunochemistry technologies, and a full range of microbiology and central lab services, LGC offers you high-integrity analytical science and expertise spanning small and large molecules, biomarkers, molecular biology and microbiology. Operating from state-of-the-art facilities to GLP, GCP and cGMP standards, LGC also has leading analytical capabilities to support Chemical Manufacturing and Control (CMC) with particular specialties in materials science and pharmaceutical analysis. With a dedicated team of scientists focused on providing laboratory services to help accelerate the development of new medicines. We offer comprehensive analytical solutions to meet the requirements for the regulatory compliance of your drug substance and drug product. Our expertise and capabilities provide support to the complex challenges faced in drug development and in solving issues at all stages of manufacture. We work on behalf of clients from all over the world and our consultative, science driven approach ensures our clients receive the highest quality data. Our flexible and tailored services follow the same rigorous principles for all experimental work, so whether you require non-regulated discovery or full regulatory studies, you know that your samples are in safe hands. For information on our range of drug development services, please visit: http://www.lgcgroup.com/dds
Просмотров: 922 LGC Group video
Alzheimer’s Drug Development: What’s Possible on the Path to 2025?
A new paper from a group of Alzheimer’s experts outlines what’s needed to meet the federal government’s goal of effective prevention or treatment by 2025. Lead author Jeffrey Cummings, MD, ScD, gives the lowdown.
Просмотров: 198 Cleveland Clinic
Simon-Kucher Expert Talk: Drug pricing and market access
Dr. Josee Hulshof, Senior Director at Simon-Kucher & Partners Strategy & Marketing Consultants talks about pricing, reimbursement and market access of pharmaceutical products. Access to necessary healthcare is perceived as a patient right in many parts of the world. Governments, employers, private insurers and patients have to provide budgets for this purpose. Due to new treatments, aging populations and hampered economic growth, the willingness and ability to finance these budgets is shrinking. A big challenge for pharmaceutical companies. Josee Hulshof explains how to handle these challenges.
Просмотров: 8152 Simon-Kucher & Partners
Drug Discovery using Bioinformatics CORRIDOR OF KNOWLEDGE vol.93
Who ever heard about the terminology, bioinformatics? This is a new area of study that merged biology and information technology, developing and improving methods for storing, retrieving, and analyzing biological data. The characteristics of human beings are built in DNA molecules that encode the genetic instructions used in the development and functioning of all known living organisms. The human genome has approximately 3 billion base pairs of DNA arranged into 46 chromosomes, which would take the power of the computer and information technology to decipher all of them. For example, if we can identify the genes that trigger cancer or Alzheimer’s disease using a computer, this will lead to the development of a new drug specifically for the disease. Here, we will look at the world of bioinformatics and the research for new drug development. A 2013 production
Просмотров: 1021 中央大学公式YouTube
MIMESIS, Mimicking viruses strategies for innovative drug discovery
ENYO Pharma is a privately held biopharmaceutical company with an innovative drug discovery approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. MIMESIS project is completing the scaling-up of ENYO Pharma’s innovative drug discovery engine with the support of the European Commission. With €3.6 million spending over 24 months, ENYO Pharma will lead five therapeutic starting points to modulate the function of novel human targets. This holds the promise for new drug development for many indications with still unmet needs and for the access to new treatments in the future. ---------------------------------------------------------------------------------------- Subscribe to ENYO Pharma: https://goo.gl/S6pW6t ---------------------------------------------------------------------------------------- ENYO Pharma's social media: LinkedIn: https://linkedin.com/company/Enyo-Pharma Twitter: https://www.twitter.com/EnyoPharma ---------------------------------------------------------------------------------------- Visit our website: http://www.enyopharma.com Contact us: contact@enyopharma.com
Просмотров: 618 ENYO Pharma
Risk Management In Portfolio Planning For Optimal Drug Development: Audio Educator
Click here for more Information:http://www.audioeducator.com/pharma-biotech/risk-management-103013.html Risk Management In Portfolio Planning For Optimal Drug Development Presented By:Vladimir Shnaydman, Ph.D Know the Best Practices for Documentation of Medical Necessity, Critical Care and Other Timed Services! More Videos: - http://www.youtube.com/user/audioeducator2 You can also connect with us on Twitter, Facebook, Google+ and LinkedIn and get the most updated news and views, expert advice and tips to help resolve your coding, billing & compliance dilemmas quickly and accurately. Connect with us on Twitter: - https://twitter.com/audioeducator Facebook: - https://www.facebook.com/pages/AudioEducator/244912592201260 LinkedIn: - http://www.linkedin.com/company/audio-educator Google+: - https://plus.google.com/102668946943256059069/posts
Просмотров: 239 AudioEducator
Lars Carlsson: Machine Learning For Smarter Drug Discovery
Discovering new drugs is becoming more costly. Here you will hear about some examples of how AstraZeneca is trying to improve the drug discovery phases through the use of machine learning.
Просмотров: 1108 RISE SICS
FDA Provides Guidance to Identify Gaps in Development Plan
Promoting Successful Translational Research: http://launchpad.ucsf.edu. Drs. Michael Matthay and Kathleen Liu describe their experience in taking a novel stem cell therapy for acute lung injury into clinical trials. Their work, in collaboration with Drs. Jae Woo Lee and Carolyn Calfee, produced compelling efficacy and safety data. However, early interactions with the FDA and guidance from Catalyst Awards adviser, Dr. David Savello, provided valuable insights that guided their research approach which have resulted in the approval to initiate a Phase I clinical study. Learn more at http://launchpad.ucsf.edu
Просмотров: 1001 ctsiatucsf
Deep Learning for Drug Discovery
Slides: https://bayesgroup.github.io/bmml_sem/2018/Polykovskiy_Deep%20Learning%20for%20Drug%20Discovery.pdf Neural networks and other machine learning models have recently been applied to many biological problems, including drug discovery. In this field, different kinds of generative models were applied to generate novel molecular structures in forms of strings and graphs. Along with the general toolbox of neural networks, multiple novel ideas were introduced to build generators of molecules, including models working with data represented as graphs. In my talk, I will give an overview of the drug discovery pipeline and how machine learning can be applied on each step. I will also cover many novel ideas and tricks used in this field, that can be extended to other domains.
Просмотров: 357 BayesGroup.ru
Computational Drug Discovery with Deep Learning - Olexandr Isayev, University of North Carolina
This presentation took place at the RE.WORK Deep Learning Summit held in Boston on 26-27 May 2015: https://www.re-work.co/events/deep-learning-boston-2015 Computational drug discovery is an effective strategy for accelerating drug discovery and development process. Because of the dramatic growth of biological and small molecule data, the applicability of computational methods like data mining, machine learning has been extended and broadly applied to nearly every stage in the drug discovery and development workflow. Over the past year, computational drug discovery with Deep learning (DL) is rapidly emerging. DL allows for multi-task learning, procedure of learning several tasks at the same time with the aim of mutual benefits. DL can also be exploited for representation learning and dimensionality reduction. In this talk, I present an overview of these developments, platforms and early successful applications in our lab as well as in the field. Olexandr Isayev is a Research Scientist at UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. In 2008, Olexandr received his Ph.D. in computational chemistry. He was Postdoctoral Research Fellow at the Case Western Reserve University and scientist at the government research lab before joining UNC in 2013. Olexandr received “Emerging Technology Award” from the American Chemical Society (ACS) and the GPU computing award from NVIDIA in 2014. His research interests focus on making sense of chemical data with molecular modeling and machine learning. #reworkDL
Просмотров: 3362 RE•WORK
How to Complete the Prescription Drug Template
The Centers for Medicare & Medicaid Services (CMS) requires healthcare issuers to complete a number of templates as part of their Qualified Health Plan (QHP) Applications. The Prescription Drug Template collects formulary information associated with an issuer’s QHPs. To learn more about the QHP certification process, visit https://www.qhpcertification.cms.gov.
Просмотров: 283 CMSHHSgov
Drug Discovery: Capital and Time
This seminar series provides an introduction to strategic and tactical planning for small molecule and antibody therapeutics. Those who attend the four sessions will understand how to determine unmet need, evaluate the competitive landscape, use integrative translational informatics to pick targets, manage a complicated interdisciplinary process, and plan for an optimal commercial exit. This series is appropriate for graduate students, post-docs and faculty who conduct or plan to conduct translational science focused on drug development - and it is also one of the few courses to provide instruction in drug development specifically for biomedical researchers.
Просмотров: 71 UCLA CTSI
Biologic Drugs and Biosimilars
What are biologic drugs? What about biosimilars? In a previous video we compared brand name and generic drugs. (https://www.youtube.com/watch?v=vqXrfzWgDkE) But we kind of left out a major player in the world of medicines; biologic drugs. These complicated little guys probably deserve a video all to themselves. Call them what you will -biologics, biotherapeutic medicines, or biopharmaceuticals- they're topic of this week's HealthCare triage. We had tons of help from Healthcare Triage intern Rachel Hoffman on this episode! Those of you who want to read more can go here: http://theincidentaleconomist.com/wordpress/?p=68795 John Green -- Executive Producer Stan Muller -- Director, Producer Aaron Carroll -- Writer Mark Olsen -- Graphics http://www.twitter.com/aaronecarroll http://www.twitter.com/crashcoursestan http://www.twitter.com/johngreen http://www.twitter.com/olsenvideo And the housekeeping: 1) You can support Healthcare Triage on Patreon: http://vid.io/xqXr Every little bit helps make the show better! 2) Check out our Facebook page: http://goo.gl/LnOq5z 3) We still have merchandise available at http://www.hctmerch.com
Просмотров: 46357 Healthcare Triage
TEDxBoston - Dr Jay Bradner - Opensource Drug Discovery
"ClC1=CC=C(C2=N[C@@H](CC(OC(C)(C)C)=O)C3=NN=C(C)N3C4=C2C(C)=C(C)S4)C=C1" Dr. Jay Bradner Research Scientist and Instructor in Medicine at Harvard and Dana Farber Cancer Institute, shares his breakthrough approach for subverting the aggressive behavior of cancer by reprogramming a cell's fundamental identity . . . and he's giving the secrets away in order to spur open-source drug discovery. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Просмотров: 16453 TEDx Talks
4SC CEO Jason Loveridge on fast-to-market strategy for cancer drug development
4SC's product pipeline 3 key compounds: Resminostat, 4SC-202 and 4SC-208 • Resminostat in pivotal studies in… o CTCL o Advanced liver cancer • 4SC-202 in Phase II studies in… o Melanoma o Gastrointestinal cancers • 4SC-208 in preclinical development Vision for 2020 • To be on the market with resminostat in CTCL • Pivotal study for resminostat in advanced liver cancer has majority of patients recruited • Efficacy shown for 4SC-202 in combination with checkpoint inhibitors / partnerships agreed • Proof-of-concept demonstrated for 4SC-208 Video produced by Dr. Reuter Investor Relations - www.dr-reuter.eu
Просмотров: 232 4SC AG
Pharmaceutical AI Strategy Executive Strategy Coaching Program
A strategy program for the CEOs and board members of pharmaceutical and biotechnology companies specifically designed to maximize shareholder value, help implement AI and Blockchain systems across the board, identify and evaluate acquisition and partnership opportunities and use geographic arbitrage to acquire and use data.
Просмотров: 483 Insilico Medicine, Inc.
Trump’s Pharma First Drug Plan
Trump's plan for lowering the cost of drugs is to make citizens of other countries pay more for their drugs; it’s perverse says Economist Dean Baker Visit http://therealnews.com for more stories and help support our work by donating at http://therealnews.com/donate.
Просмотров: 3926 The Real News Network
China - world power again | DW Documentary
China is on its way to becoming a socialist world power. After a time of revolution and reform, the country is entering a new era. As President Xi Jinping forges the path forward, a question remains: will the Chinese people continue to support him? At the Chinese Communist Party’s convention in fall of 2017, President Xi Jinping sent a clear message to the world: China is entering a new era. Many believe President Xi Jinping has brought the party back on track and has secured the support of the Chinese people. Speaking to delegates in October, Xi said it was time for the nation to be a global leader that could set an example on economic, political and environmental matters. Part of his plan for economic growth is Made in China 2025, an initiative that draws from Germany’s Industry 4.0 plan and aims to make advancements across many industries, including automotive, aircraft, pharmaceutical, and artificial intelligence. _______ Exciting, powerful and informative – DW Documentary is always close to current affairs and international events. Our eclectic mix of award-winning films and reports take you straight to the heart of the story. Dive into different cultures, journey across distant lands, and discover the inner workings of modern-day life. Subscribe and explore the world around you – every day, one DW Documentary at a time. Subscribe to DW Documentary: https://www.youtube.com/channel/UCW39zufHfsuGgpLviKh297Q?sub_confirmation=1# For more information visit: http://www.dw.com/en/tv/docfilm/s-3610 Instagram https://www.instagram.com/dwdocumentary/ Facebook: https://www.facebook.com/dw.stories DW netiquette policy: http://www.dw.com/en/dws-netiquette-policy/a-5300954
Просмотров: 835955 DW Documentary
Why Prescription Drugs Cost So Much | Michael Rea | TEDxKC
Would you be mad if you found out you were paying as much as 2000% more than your neighbor for a prescription? Furious, Michael Rea left his job as a pharmacist eight years ago to pursue a solution to the runaway cost of prescription drugs. Dr. Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr. Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Просмотров: 26620 TEDx Talks
Skyrocketing Drug Prices: A Bitter Pill to Swallow
While new discoveries in medicine have fueled the drug development industry, our ability to control costs and broaden access to drugs has decreased. What is the role of academic medical centers to control such costs? How can our basic science knowledge and impact on healthcare policy contribute to lowering drug costs? Moderated by Carolyn Johnson, The Washington Post reporter who covers the intersection between business and health. Panelists: Jeremy Greene, M.A., M.D., Ph.D. and Redonda Miller, M.B.A., M.D. #JHMBootCamp View more from the 2018 Science Writers' Boot Camp at: https://www.hopkinsmedicine.org/institute_basic_biomedical_sciences/news_events/2018_The_Price_We_Pay.html
Просмотров: 166 Johns Hopkins Medicine
Webinar: 5 Qualities to Consider When Selecting CPUs for Early Drug Development
http://wcct.com When it comes to selecting the right sites for Phase 1 clinical trials, typical criteria includes some combination of the following factors: -Experience of PI/Nursing Staff -Bed space -Access to the patient population -Access to the necessary equipment to operationalize the study -Experience in similar studies -Geographic location -Enrollment capability -Contract/budget negotiation structure -Regulatory history -Cost However, when clinical Phase 1 units fulfill the items on the checklist, a deep analysis of their operations tends to be forgotten, leaving other critical factors overlooked during site selection, such as: 1.Internal costing exercises 2.Staff optimization 3.Risk Mitigation and Contingency Planning 4.Vendor Usage and Selection 5.Execution of complex protocol requirements In this webinar, WCCT Global discussed the importance of evaluating these five factors during the selection of Phase 1 clinical sites for large early clinical development programs. To learn more about WCCT's capabilities in conducting Phase 1 clinical trials, visit us here: http://wcct.com/clinical-pharmacology-units-research-sites-services/early-phase-research/
Просмотров: 110 WCCT Global
Nursing Process Overview: ADPIE (Assessment, Diagnosis, Planning, Implementation and Evaluation)
This video provides a a brief overview of the nursing process. It is good for beginners and students preparing for the NCLEX-RN. More videos are available about specific parts of the nursing process in this playlist: https://www.youtube.com/playlist?list=PLs4oKIDq23AfdIxE8NvwnhbORnb_dE_RJ Critical Thinking Part 1: Definition, Connection to the Nursing Process, Benefits and Levels. http://youtu.be/GnrPz1AlnW0 Critical Thinking Part 2: Components and Development http://youtu.be/ovu6Q1orjH4 To learn about SMART goals see http://www.youtube.com/watch?v=k9TuE4--IuY&feature=share&list=UUmjoIHKlxtimgqZEAauWnHw Sample Assessment: http://youtu.be/rssf7Y8xd8A
Просмотров: 168686 NurseKillam
Westar® RU and RS Cartridge Components
Patient needs are evolving and cartridge components need to support safe self-administration, dose accuracy and ease of use with a device. Drug development strategy can be simplified and manufacturing streamlined by selecting cartridge plungers in a ready-to-use-format.
Просмотров: 152 West Pharmaceutical Services, Inc.
Pharmaceutical Sales Management  Drug Representative Case Study
http://www.getpharmaceuticalsalesjob.com presents former Pharmaceutical Product Marketing and Sales Manager Clint Cora talking about the common case of promoting newer medications and a strategy for drug representatives. This is a great case for pharmaceutical sales management to review. Clint is a fourteen year veteran in the pharmaceutical sales industry and offers a free webinar on drug representative careers at the website mentioned above.
Просмотров: 4918 Clint Cora
Drug Discovery with Machine Learning
In today's episode, Kyle chats with Alexander Zhebrak, CTO of Insilico Medicine, Inc. Insilico self describes as artificial intelligence for drug discovery, biomarker development, and aging research. The conversation in this episode explores the ways in which machine learning, in particular, deep learning, is contributing to the advancement of drug discovery. This happens not just through research but also through software development. Insilico works on data pipelines and tools like MOSES, a benchmarking platform to support research on machine learning for drug discovery. The MOSES platform provides a standardized benchmarking dataset, a set of open-sourced models with unified implementation, and metrics to evaluate and assess their performance.
Просмотров: 101 Data Skeptic
What are the benefits of using SPR in FBDD and/or drug discovery
Is it possible to identify true hits just based on affinity data? Join our experts and discuss the value of SPR data—what you can gain and how to best utilize the information generated. SPR-based biosensors have emerged over the past decade as a powerful tool in fragment-based drug discovery (FBDD) due to the sensitivity required to observe binding interactions of low-affinity and low-molecular weight compounds with target proteins. This offers not only novel ways of hit finding, but also more efficient ways to identify and advance true hits for chemistry and later stage biology. Quantitative binding information for ranking fragments by affinity and ligand efficiency is critical to support ongoing structure-activity efforts during fragment hit-to-lead development. In this discussion forum, the basic strategy of the technology used, examples of screening/lead finding projects, as well as how this critical information drives decision-making in drug discovery will be covered. Facilitators: Dr Olof Karlsson and Dr Paul Belcher. Dr Olof Karlsson is a Senior Scientist in the Applications Department, Protein Analysis R&D, GE Healthcare, Uppsala, Sweden. Prior to joining former Biacore AB, Olof was a Scientist at the Department of Molecular Biology, Astra Hässle AB (now AstraZeneca, R&D), Umeå, Sweden (1997-1999). He received his PhD in biochemistry from the Department of Biochemistry, Umeå University, Umeå, Sweden in 1997 and his BSc degree in chemistry from Umeå University in 1990. Dr Paul Belcher is a Development Leader, label free interaction analysis at GE Healthcare. He received his PhD in organic chemistry from the University of Newcastle upon Tyne in the United Kingdom in 2003. During his postdoctoral training, he worked under George Pettit at Arizona State University on the first total synthesis of the natural product dolastatin 16, a potential cancer therapeutic. While at Arizona State, Paul established a label-free screening program for screening/characterization of large libraries of compounds to enable the development of synthetic probes to challenging targets. At GE Healthcare, Paul's focus has been on the value of drug-target binding kinetics for investigating structure-activity relationships and drug efficacy. He also works on fragment-based lead discovery, interacting predominately with small molecule screening groups within academia and industry to implement and optimize label-free methods for drug discovery. He is a frequent speaker and has given over 100 lectures at pharma/biotech industry sites and universities in North America.
Просмотров: 3566 GE Healthcare Life Sciences
Pharmacogenomics: Paving the Way to Improved Drug Development and Healthcare
Pharmacogenomics:Paving the Way to Improved Drug Development and Healthcare
Просмотров: 188 Labcompare
Lessons from the Child of an Addict | Emily Smith | TEDxErie
Emily is an advocate for mental health and disability rights because of the firsthand experience she has with both subjects. She writes about her experiences and life lessons she has learned from growing up with an estranged mother who was ridden with a drug addiction. Her future plans include going to graduate school and becoming a drug and alcohol addictions counselor. Emily Smith is a native of Scranton, Pennsylvania. She now resides in Fairfax, Virginia, where she is a sophomore in George Mason University’s undergraduate psychology program. She also minors in photography, her lifelong passion. She is an advocate for mental health and disability rights because of the firsthand experience she has with both subjects. She has participated in many lobbying events on Capitol Hill for complex rehab technology and other disability issues. She is also a writer for The Odyssey, a university wide publication, where she writes about her experiences and life lessons she has learned from growing up with an estranged mother who was ridden with a drug addiction. Her volunteer work includes the Muscular Dystrophy Association as well as mentoring children with disabilities and working with literacy foundations to offer children the gift of reading and education. Her future plans include going to graduate school and becoming a drug and alcohol addictions counselor. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Просмотров: 44184 TEDx Talks
Drugmaker Pfizer plans to raise prices on 41 prescription drugs
Navigating the drug pricing maze can be very confusing and frustrating. Bob Herman, health care business reporter for Axios, joins CBSN to discuss his article on drug pricing in America. Subscribe to the CBS News Channel HERE: http://youtube.com/cbsnews Watch CBSN live HERE: http://cbsn.ws/1PlLpZ7 Follow CBS News on Instagram HERE: https://www.instagram.com/cbsnews/ Like CBS News on Facebook HERE: http://facebook.com/cbsnews Follow CBS News on Twitter HERE: http://twitter.com/cbsnews Get the latest news and best in original reporting from CBS News delivered to your inbox. Subscribe to newsletters HERE: http://cbsn.ws/1RqHw7T Get your news on the go! Download CBS News mobile apps HERE: http://cbsn.ws/1Xb1WC8 Get new episodes of shows you love across devices the next day, stream CBSN and local news live, and watch full seasons of CBS fan favorites like Star Trek Discovery anytime, anywhere with CBS All Access. Try it free! http://bit.ly/1OQA29B --- CBSN is the first digital streaming news network that will allow Internet-connected consumers to watch live, anchored news coverage on their connected TV and other devices. At launch, the network is available 24/7 and makes all of the resources of CBS News available directly on digital platforms with live, anchored coverage 15 hours each weekday. CBSN. Always On.
Просмотров: 8491 CBS News
Peace Corps Reponse Volunteer Works on Drug Rehabilitation Planning in the Philippines
Janett Forte is currently working as a Peace Corps Response Volunteer in the Philippines where she is using her background in teaching, training, and social work in her assignment as a drug rehabilitation planning officer at the Malinao Treatment Rehabilitation Center. Janett is one of the first to serve as a Peace Corps Response Volunteer without previous Peace Corps experience.
Просмотров: 2775 Peace Corps
Advancing Drug Development with Digital Health
In this webinar, industry leaders Validic, Duke Clinical Research Institute and Medidata discuss how digital health is disrupting the way the pharmaceutical industry gathers data from clinical trial participants. By arming participants with wearable and FDA Class II medical devices, sensors and applications, pharma and CROs can remotely collect activity data along with key biometrics. This stands to significantly restructure the drug development process, allowing companies to bring a drug to market more efficiently and cost-effectively while also improving the clinical trial participants’ experience. Pharmaceutical companies looking to implement a digital health strategy can view this on-demand webinar to: - Learn four key ways pharma and CROs can leverage participant data from digital health devices. - Read real examples of how digital health data is being utilized by pharma. - Discover the benefits, for both pharma and trial participants, of integrating digital health data into drug development.
Просмотров: 377 Validic
history of japan
http://billwurtz.com patreon: http://patreon.com/billwurtz spotify: https://play.spotify.com/artist/78cT0dM5Ivm722EP2sgfDh itunes: http://itunes.apple.com/us/artist/bill-wurtz/id1019208137 twitter: http://twitter.com/billwurtz instagram: http://instagram.com/notbillwurtz vine: http://vine.co/billwurtz donate: http://paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=VXTWA8CDYP4RJ
Просмотров: 45537426 bill wurtz
Clinton pushes plan to address rising drug costs
DES MOINES, Iowa (AP) -- Hillary Rodham Clinton is outlining a sweeping plan to hold down the rising cost of prescription drugs and target drug companies that flood the airwaves with ads. The Democratic presidential candidate said at a forum in Iowa on Tuesday that she wants to protect consumers while promoting innovation and putting an end to profiteering in the pharmaceutical industry. Her plan would place a monthly cap of 50 on covered out-of-pocket prescription drug costs to help patients with chronic or serious health conditions. It would also deny tax breaks for televised direct-to-consumer advertising and require drug companies that receive taxpayers' support to invest in research and development. "It has gotten to the point where people are being asked to pay, not just hundreds but thousands of dollars for a single pill," Clinton said. "And I can tell you, that is not the way a market is supposed to work. That is bad actors making a fortune off of people's misfortune." Clinton was outlining details of her plan as part of a weeklong push to defend President Barack Obama's health care law. The former secretary of state has credited the overhaul with driving down the rate of uninsured Americans and chastised Republicans who have sought its repeal. Clinton said she wants to make sure the law works for everyone. She said she'll put insurance providers "on notice" that they need to help people afford the medical care that they require. "Insurance companies have been keeping the savings for themselves and shifting more costs on to families. My plan will address that," she said. Clinton's support for Obama's controversial health care law is the latest example of her campaign attaching itself to Obama's record amid a competitive Democratic primary. Also at play is Vice President Joe Biden's interest in joining the race, though it's far from certain that he will. The health care law has been credited with helping reduce the number of uninsured people from 48.6 million in 2010 to 29 million people in the first three months of 2015. A recent poll by the nonpartisan Kaiser Family Foundation found that 72 percent of Americans say the cost of prescription drugs is unreasonable. Clinton's plan received a chilly reception from the pharmaceutical industry, which said it would restrict patients' access to medicine. "Secretary Clinton's proposal would turn back the clock on medical innovation and halt progress against the diseases that patients fear most," John Castellani, head of the Pharmaceutical Research and Manufacturers of America, said in a statement. Clinton said she wanted to "both protect consumers and promote innovation, while putting an end to profiteering." Republicans accused Clinton of embracing the health care law to draw attention away from inquiries over her use of a private email system as Obama's secretary of state. Clinton and her husband, former President Bill Clinton, have been paid at least .8 million for appearances at events sponsored by pharmaceutical companies or associations representing pharmacy industry interests, according to tax and financial records between 2001 and 2014. Health care and the rising cost of prescription drugs have gained attention in the Democratic campaign. Clinton's main challenger, Vermont Sen. Bernie Sanders, has pushed the creation of a single-payer health care system and introduced legislation that would allow Medicare to negotiate lower drug prices with pharmaceutical companies and let consumers import prescription medication from Canada, where costs are cheaper. "The pharmaceutical industry has become a health hazard for the American people," Sanders said in a statement Tuesday. As she did during her 2008 presidential campaign, Clinton would seek to allow Medicare to use its large purchasing power to negotiate lower drug prices. Her plan also seeks to increase competition for traditional generic versions of specialty drugs to drive down prices and offer consumer choice, including allowing people to import foreign drugs. The proposal would require health insurance plans to place a monthly and annual limit on covered out-of-pocket prescription drug costs for individuals. The campaign estimated that up to 1 million Americans could benefit from the plan annually. 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use. Follow us on Twitter @Local12 and LIKE us on Facebook for updates!
Просмотров: 187 LOCAL 12
Porter's Five Forces Model - Example:  Pharmaceutical
Porter's Five Forces Model - Example: Pharmaceutical Industry In 1979, Harvard Business Review published How Competitive Forces Shape Strategy by a young economist and associate professor, Michael E. Porter. The main purpose of Porters Five Forces is to find a position in an industry where a company can defend itself against competitive forces or it can influence them in its favour. A strategist can analyse, any market by rating each competitive force as high, medium, low in strength and rate as follows. If we look at the pharmaceutical industry worldwide, the five forces could be rated as follows. Competition among existing rivalry is high as key players Pfizer, Glaxo Smith Kline, Bayer and Eli Lily compete closely and strongly in the market. The threat of new entrants is seen as low, since high entry barriers due to costs associated with research , development of new drugs and government regulatory barriers make it difficult for new entrants. The threat of substitutes could also be seen as medium as Generic drug companies do not have the high costs associated with the research and development of new drugs and this allows them to sell at cheaper price points. The bargaining power of buyers could be rated as medium because hospitals, health care organizations can exert pressure on Pharmaceutical companies to keep prices in check. Generic drugs give patients lower price options. The bargaining power of suppliers is low as sales for the pharmaceutical industry concentrate in a handful of large players and that has decreased the bargaining power of suppliers. Overall, based on the above analysis of Porter's Five Forces, we can conclude that the pharmaceutical industry is not attractive for new entrants. Reference: Porter, M.E. (March/April 1979). "How Competitive Forces Shape Strategy". Harvard Business Review. Created at http://www.b2bwhiteboard.com
Просмотров: 17753 B2Bwhiteboard
Mackay Says Pfizer in `Golden Age' of Drug Discovery: Video
April 7 (Bloomberg) -- Martin Mackay, president of pharmaceutical research at Pfizer Inc., the world's biggest drugmaker, talks with Bloomberg's Susan Li and Paul Gordon about the company's business strategy and outlook for new products. (Source: Bloomberg)
Просмотров: 492 Bloomberg
Marine Diesel Engine and laminated bilge stringer istall.  SDP #41
Not a whole lot of progress but that was mostly due to the road trip we took down to florida with my father. His recent knee surgery required that I help with the driving. We made it work to our advantage and with various stops for materials and knowledge that help advance the project. We pick up a load of lead, interiew the owner of Beta Marine as well as many stops at various marinas, surplus stores and salvage yards. All and all, a great trip. This is this is the story of a complete boat owning and boat building novice and his family, constructing a 41’ full displacement trawler yacht in the backyard of their upstate New York home. While I consider myself a fairly advanced amateur woodworker and DIY guy, I’ve never owned a boat before and certainly have never built one either. The naval architect, George Buehler, designed this boat, from his Diesel Duck line, with the home builder in mind. This design has been licensed for professional builders in China and Turkey, but George’s goal was always to make the large, blue water cruising boat within the reach of the average person. His commitment to a design that was attainable for the average handy person, resulted in his first book, Buehlers Backyard Boat Building, detailing the process. His designs often include building materials and fasteners available at the big box home improvement stores. George believed that a robust, comfortable and safe cruising boat could be built with less than ideal, traditional materials. While he acknowledge that less than ideal materials may limit the vessels longevity and resale value, his design would get people safely out on the water while the other guy remained landlocked saving for a design he would never be able to afford to build. Many traditionalist scoff at his mostly hard chined designs and deviation from traditional methods and materials. However his maverick approach has made the dream of crossing oceans in a home built boat a reality for many around the world. No matter what the “experts” say, his designs have been proven over and over with literally hundreds of examples cruising the worlds oceans today. Our goal is to be next! Get your Sea Dreamer Project challenge coin here: http://www.svseeker.com/wp/product/sea_dreamer-challenge-coin/ Totalboat epoxy, the official epoxy of the Sea Dreamer Project: https://www.jamestowndistributors.com/userportal/show_product.do?pid=64343&familyName=TotalBoat+5%3A1+Epoxy+Kits 20% discount code at checkout: DREAMER Atlas work gear and apparel. Every purchase through this link helps support our project: https://www.atlas46.com/index.html?tap_a=12580-4fee7f&tap_s=257018-204570 Custom saw milling and welding at DAM Enterprises: https://www.facebook.com/DAMsawmilling/ Beta Marine- Marine Diesel Engines: www.betamarinenc.com Production equipment: Camera: Canon EOS M50 Microphone: RØDE Pro Editing Software: Finalcut Pro
Просмотров: 24583 Six Points Wood Works